These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

563 related items for PubMed ID: 17323035

  • 1. [Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective?].
    Haberbosch W.
    Herz; 2007 Feb; 32(1):51-7. PubMed ID: 17323035
    [Abstract] [Full Text] [Related]

  • 2. Cardiovascular risk and cardiometabolic protection: role of glitazones.
    Petrazzi L, Grassi D, Polidoro L, D'Aurelio A, Croce G, Properzi G, Tiberti S, Desideri G, Ferri C.
    J Nephrol; 2008 Feb; 21(6):826-35. PubMed ID: 19034866
    [Abstract] [Full Text] [Related]

  • 3. Effects of pioglitazone on lipid and lipoprotein metabolism.
    Betteridge DJ.
    Diabetes Obes Metab; 2007 Sep; 9(5):640-7. PubMed ID: 17697057
    [Abstract] [Full Text] [Related]

  • 4. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
    Miyazaki Y, DeFronzo RA.
    Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
    [Abstract] [Full Text] [Related]

  • 5. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).
    Wilcox R, Kupfer S, Erdmann E, PROactive Study investigators.
    Am Heart J; 2008 Apr; 155(4):712-7. PubMed ID: 18371481
    [Abstract] [Full Text] [Related]

  • 6. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.
    Irons BK, Greene RS, Mazzolini TA, Edwards KL, Sleeper RB.
    Pharmacotherapy; 2006 Feb; 26(2):168-81. PubMed ID: 16466323
    [Abstract] [Full Text] [Related]

  • 7. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
    Krentz A.
    Diabetes Metab Res Rev; 2009 Feb; 25(2):112-26. PubMed ID: 19219860
    [Abstract] [Full Text] [Related]

  • 8. Thiazolidinediones: comparison of long-term effects on glycemic control and cardiovascular risk factors.
    Gegick CG, Altheimer MD.
    Curr Med Res Opin; 2004 Jun; 20(6):919-30. PubMed ID: 15200751
    [Abstract] [Full Text] [Related]

  • 9. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U, Pop-Busui R, Eagle KA.
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [Abstract] [Full Text] [Related]

  • 10. The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. An open-label observational study.
    Sarafidis PA, Lasaridis AN, Nilsson PM, Mouslech TF, Hitoglou-Makedou AD, Stafylas PC, Kazakos KA, Yovos JG, Tourkantonis AA.
    Metabolism; 2005 Sep; 54(9):1236-42. PubMed ID: 16125536
    [Abstract] [Full Text] [Related]

  • 11. Statins and diabetes.
    Carmena R, Betteridge DJ.
    Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
    [Abstract] [Full Text] [Related]

  • 12. CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone.
    Betteridge DJ.
    Fundam Clin Pharmacol; 2009 Dec; 23(6):675-9. PubMed ID: 19744248
    [Abstract] [Full Text] [Related]

  • 13. The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin.
    Tonstad S, Retterstøl K, Ose L, Ohman KP, Lindberg MB, Svensson M.
    Metabolism; 2007 Sep; 56(9):1285-92. PubMed ID: 17697874
    [Abstract] [Full Text] [Related]

  • 14. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study.
    Langenfeld MR, Forst T, Hohberg C, Kann P, Lübben G, Konrad T, Füllert SD, Sachara C, Pfützner A.
    Circulation; 2005 May 17; 111(19):2525-31. PubMed ID: 15883215
    [Abstract] [Full Text] [Related]

  • 15. Cardiovascular manifestations of insulin resistance.
    Chahwala V, Arora R.
    Am J Ther; 2009 May 17; 16(5):e14-28. PubMed ID: 19114874
    [Abstract] [Full Text] [Related]

  • 16. Long-term lipid effects of pioglitazone by baseline anti-hyperglycemia medication therapy and statin use from the PROactive experience (PROactive 14).
    Spanheimer R, Betteridge DJ, Tan MH, Ferrannini E, Charbonnel B, PROactive Investigators.
    Am J Cardiol; 2009 Jul 15; 104(2):234-9. PubMed ID: 19576353
    [Abstract] [Full Text] [Related]

  • 17. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.
    Defronzo RA, Mehta RJ, Schnure JJ.
    Hosp Pract (1995); 2013 Apr 15; 41(2):132-47. PubMed ID: 23680744
    [Abstract] [Full Text] [Related]

  • 18. Metformin and pioglitazone: Effectively treating insulin resistance.
    Staels B.
    Curr Med Res Opin; 2006 Apr 15; 22 Suppl 2():S27-37. PubMed ID: 16914073
    [Abstract] [Full Text] [Related]

  • 19. Pleiotropic effects of thiazolidinediones.
    Rizos CV, Liberopoulos EN, Mikhailidis DP, Elisaf MS.
    Expert Opin Pharmacother; 2008 May 15; 9(7):1087-108. PubMed ID: 18422468
    [Abstract] [Full Text] [Related]

  • 20. Long-term pioglitazone therapy improves arterial stiffness in patients with type 2 diabetes mellitus.
    Harashima K, Hayashi J, Miwa T, Tsunoda T.
    Metabolism; 2009 Jun 15; 58(6):739-45. PubMed ID: 19446110
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.